Drug Type Dual payload Antibody drug conjugate (Dual payload ADC) |
Synonyms IMD 2113, IMD2113 |
Action antagonists, agonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TLR7 agonists(Toll like receptor 7 agonists), TLR8 agonists(Toll like receptor 8 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
Molecular FormulaC26H24FN3O6 |
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N |
CAS Registry1599440-33-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | IND Application | - | - | |
Neoplasms | Preclinical | China | 28 Apr 2025 |